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ABSTRACT
While research on T cell exhaustion in context of cancer particularly focuses on CD8C cytotoxic T cells, the
role of inhibitory receptors on CD4C T-helper cells have remained largely unexplored. TIGIT is a recently
identified inhibitory receptor on T cells and natural killer (NK) cells. In this study, we examined TIGIT
expression on T cell subsets from CLL patients. While we did not observe any differences in TIGIT expression
in CD8C T cells of healthy controls and CLL cells, we found an enrichment of TIGITC T cells in the CD4C T
cell compartment in CLL. Intriguingly, CLL patients with an advanced disease stage displayed elevated
numbers of CD4C TIGITC T cells compared to low risk patients. Autologous CLL-T cell co-culture assays
revealed that depleting CD4C TIGITC expressing T cells from co-cultures significantly decreased CLL viability.
Accordingly, a supportive effect of TIGITCCD4C T cells on CLL cells in vitro could be recapitulated by
blocking the interaction of TIGIT with its ligands using TIGIT-Fc molecules, which also impeded the T cell
specific production of CLL-prosurvival cytokines. Our data reveal that TIGITCCD4CT cells provide a
supportive microenvironment for CLL cells, representing a potential therapeutic target for CLL treatment.
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Chronic lymphocytic leukemia (CLL) is a B cell malignancy,
which is associated with substantial T subset skewing and T cell
defects.1 In particular, we and others have previously shown that
T cells from CLL patients show typical signs of T cell exhaustion,
as they exhibit increased expression of inhibitory receptors and
defects in proliferation, cytokine expression and synapse forma-
tion.2-5 In general, T cell exhaustion is the functional silencing of
antigen experienced T cells, contributing to peripheral T cell toler-
ance to avoid excessive immune pathology during T cell
responses,6 a process initially described during chronic viral infec-
tions7. However, T cell exhaustion was also found to occur in can-
cer and is supposed to significantly contribute to immune evasion
of cancer cells by rendering cancer specific T cells non-functional.8
A key molecule in T cell exhaustion was found to be programmed
death-1 (PD-1), which functionally impedes T cell receptor (TCR)
mediated signaling on exhausted T cells.9 In addition to PD-1, a
number of different inhibitory receptors were recently found to be
associated with T cell exhaustion. The concept that the exhausted
phenotype could be reversed by simply blocking these inhibitory
receptors by monoclonal antibodies led to a renaissance of cancer
immune therapy with specific immune checkpoint blockade using
PD-1 antibodies being considered as a major breakthrough in can-
cer treatment.10 Considering the strength of checkpoint blockade,
it is important to investigate further inhibitory receptors aside of
PD-1 to increase efficacy and minimize side effects of this treat-
ment approach, especially in light of the fact that not all cancer
entities respond to PD-1 blockade. For CLL, no clear effects were
noticed for single agent anti-PD-1 therapy (pembrolizumab)
except for patients with Richter’s syndrome, whereas at least par-
tial responses were reported for CLL patients receiving anti-PD-1
therapy (nivolumab) combined with ibrutinib.11,12
TIGIT (T cell immunoreceptor with Ig and ITIM domains)
is a recently identified inhibitory receptor which is expressed
on T cells, natural killer (NK) and NKT cells.13,14 TIGIT has a
cytoplasmic tail containing an immunoglobulin tail tyrosine
(ITT)- like phosphorylation motif and an immunoreceptor
tyrosine-based inhibitory motif (ITIM)(15). The natural ligands
for TIGIT are the poliovirus receptors (PVR) CD155 and
CD112. TIGIT signaling involves the recruitment of the phos-
phatase SHIP1 to the ITIM and downstream inhibition of
NF-kB, PI3 K and MAPK pathways.16,17 PVRs are widely
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expressed on different cell types and were also found to be
expressed on a number of cancer cells.18-21 In parallel, TIGITC
tumor infiltrating CD8C T cells could be detected in small-cell
lung cancers, colorectal cancers and melanoma.22-24 Similar to
the situation of CTLA-4 and CD28, which are sharing the same
ligands25, TIGIT competes with CD226, a costimulatory T cell
molecule for PVR binding and can directly prevent CD226 sig-
naling by impeding its homodimerization.22 Hence, agonistic
TIGIT antibodies could decrease T cell function similar to
CD226 knockdown26,27 and TIGIT inhibition was recently
shown to increase T cell functions of melanoma specific
CD8CT cells.28
In this study, we investigated expression and function of
TIGIT expressing T cells in CLL patients. We observed an
increase in TIGIT expressing CD4CT cells in CLL compared to
healthy controls and we provide evidence that TIGITCCD4CT
cells display a microenvironment important for CLL survival.
Our data propose TIGIT to be a potential target for immune
therapy in CLL.
Results
TIGIT expressing CD4C T cells are elevated in patients
with CLL
To evaluate TIGIT expression in comparison to other inhibi-
tory receptors (PD-1 and 2B4/CD244) which we previously
examined in CLL,2 we performed phenotypic characterization
of T cells from peripheral blood samples of CLL patients and
age-matched healthy controls using flow cytometry (Fig 1a and
b). In line with our previous results,2 we found that the percen-
tages of CD4C or CD8C T cells expressing 2B4 or PD-1 were
not significantly different between patients and healthy controls
(Fig 1b). However, within the CD4C but not the CD8C T cell
subset, we observed a significant increase in the percentage of
TIGITC cells in CLL patients compared to healthy controls
(Fig 1b). Most of the TIGITCCD4CT cells were also positive
for PD-1 (Fig 1c), reflected in a high correlation of PD-1 and
TIGIT expression in this T cell subset (Fig 1d). The percentage
of TIGITCCD4C T, PD-1CCD4C and PD-1CCD8CT cells
was higher in bone marrow compared to peripheral blood of
the same patient and we observed a high correlation of TIGIT,
PD-1 and 2B4 expression in peripheral blood and bone marrow
(supplementary figure S1). Notably, the inhibitory receptor
TIM-3 was not detectable on T cells from peripheral blood of
CLL patients (supplementary figure S2). Moreover, while
TIGIT expression on CD8CT cells did not correlate with
advanced disease stage or prior treatment, we found signifi-
cantly increased TIGITCCD4CT cells in patients with unmu-
tated IgVH status, with RAI stage 1/ Binet B and in treated
patients. No correlation with other prognostic factors (Zap70,
CD38, CD49 d expression or chromosomal aberrations) was
observed (Fig 1e and supplementary figure S3).
TIGIT is preferentially expressed on antigen experienced
and Th1 polarized cells in CLL
To more thoroughly evaluate TIGIT expression on T cells,
we analysed expression of TIGIT in combination with T cell
subset defining markers. In line with previous reports, we
observed a general shift towards effector memory T cell pop-
ulations as defined by CD62 L/CD45RA expression in CLL
(Fig 2a). By analyzing na€ıve (CD62 LCCD45RAC), central
memory (TCM:CD62 LCCD45RA-), effector memory (TEM:
CD62 L-CD45RA-), and terminally differentiated effector
memory (TEMRA:CD62 L-CD45RAC) CD4C and CD8CT
cells with respect to their expression of TIGIT, we found
that within the TIGITCCD4CT cells, TEMRA and na€ıve cells
were significantly enriched whereas the percentage of TCM
cells was decreased in CLL (Fig 2b). In TIGITCCD8CT cells,
Figure 1. T cells from CLL patients display elevated TIGIT expression. (a-b) Periph-
eral blood samples from CLL patients (CLL) and age-matched healthy controls (HC)
were analyzed by flow cytometry (FACS) with regard to TIGIT, 2B4 and PD-1
expression on CD4 or CD8 T cells. (c) Distribution of inhibitory receptors on TIGIT-
or TIGITC T cells. (d) Correlation of TIGIT and PD-1 expression on CD4C or CD8C T
cells. (e) Distribution of CD4CTIGITC cells in patients divided according to clinical
markers of disease burden (Rai/ Binet stage or treatment status).
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TEMRA subsets were expanded (Fig 2b). Counting the abso-
lute number of cells within the respective T cell subsets
revealed that TIGITCCD4CT cells were enriched within the
na€ıve, TEM and TEMRA subsets and CD8CTIGITCT cells
within the TEM subset in CLL (Fig 2c). We further character-
ized Th1 (CD45RA-CXCR3CCCR4-), Th2 (CD45RA-CCR3-
CCR4C), regulatory T (Treg; CD127-CD25C) and follicular
helper T (Tfh; CXCR5CPD-1C) cells and found a general
skewing towards Th1, Treg and Tfh subsets in CLL com-
pared to healthy controls (Fig 3a). While we observed a sig-
nificant increase in the percentage of TIGITCTh1 cells in
peripheral blood from CLL patients compared to healthy
controls, the absolute cell numbers of TIGITCTh1, TIGITC-
Treg as well as of TIGITCTfh cells were all significantly
Figure 2. TIGIT is particularly expressed on antigen experienced T cells. (a) T cell subsets in peripheral blood samples from CLL patients and age-matched healthy controls
(HC) were measured by FACS analysis defined by CD62 L and CD45RA. Plots represent na€ıve (Tnaive: CD62 LCCD45RAC), central memory (TCM: CD62 LCCD45RA-), effector
memory (TEM: CD62 L-CD45RA-) and terminally differentiated effector memory (TEMRA: CD62 L-CD45RAC). (b) T cell subset distribution in the TIGIT- and TIGITC T cell com-
partment. (c) Absolute cell counts (cells/mL blood) of CD4C and CD8C subsets expressing TIGIT.
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increased in peripheral blood from CLL patients compared
to healthy controls (Fig 3b and c), with no apparent correla-
tion with tumor load or treatment status (supplementary
figure S4).In addition, we found that in CLL, a significantly
smaller percentage of TIGITCCD4CT cells expressed
CD226, a costimulatory molecule competing with TIGIT for
the same ligands (Fig 3d). Further analysis of the CD8 com-
partment revealed decreased percentage of CD226 expressing
Figure 3. Absolute cell counts of TIGITCTh1, TIGITCTreg and TIGITCTfh cells are significantly increased in CLL. (a) Plot of percentages of Th1, Th2, Treg and Tfh among
CD4C T cells from controls and CLL patients. (b) Percentage of TIGIT expressing Th1, Th2, Treg and Tfh cells. (c) Absolute cell counts (cells/mL). (d) Percentage of CD226C
cells among TIGIT- versus TIGITC CD4C or CD8C cells in HCs or CLL patients.(e) Correlation of TIGIT and CD226 expression on CD4C or CD8C T cells.
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cells among TIGITCT cells compared to TIGIT- CD8CT
cells (Fig 3d) and a negative correlation of CD226 with
TIGIT expression (Fig 3e).
TIGITCCD4C but not TIGITCCD8C T cells affect in vitro
survival of autologous CLL cells
Next, we wanted to assess CLL prosurvival or proapoptotic
capacities of TIGITC CD4C and CD8C T cells. To this end,
we performed autologous CLL/T cell co-culture assays using
CD3/CD28 activated T cells which were either depleted of
TIGIT or PD-1 expressing T cells using flow cytometric cell
sorting (as outlined in the methods section; Fig 4a). Thereby
we found that absence of TIGITC cells from all T cells in
our co-culture setting resulted in significant decrease in the
percentage of viable CLL cells (Fig 4b). While absence of
PD-1C T cells had no significant effect on CLL cells, absence
of both PD-1C and TIGITC T cells again resulted in
decreased CLL viability (Fig 4b). To elucidate whether the
prosurvival impact of TIGITC T cells depends on CD4C or
CD8C T cells, we further depleted T cells from
CD4CTIGITC or CD8CTIGITC cells prior to co-culture
with CLL cells (Fig 4a). Thereby we observed that only
absence of TIGITCCD4C but not TIGITCCD8CT cells
decreased CLL cell survival (Fig 4b). In these assays, also
absence of PD-1CCD4C T cells resulted in decreased CLL
cell survival (Fig 4b). Of note, this effect on CLL survival in
these co-culture assays was not based on reduced overall
numbers of T cells, as the T/CLL cell ratio was not signifi-
cantly different in the respective assays (Fig 4c).
Blocking TIGIT interactions decreases CLL viability
and interferes with production of prosurvival cytokines
To further examine the CLL-supportive function of
TIGITCCD4CT cells, we analyzed the cytokine expression
profile of TIGITC and TIGIT- CD4CT cells using intracellular
cytokine staining (Fig 5a). We observed a significantly higher
percentage of IFNg and IL-10 producing CD4CT cells within
the TIGITC population while the percentage of IL-21 and IL-4
producing cells was comparable in TIGITC and TIGIT- subpo-
pulations (Fig 5b). In addition, low but measurable expression
levels of the ligands for TIGIT (CD112 and CD155) could be
detected on the surface of primary CLL samples as well as on
T cells (Fig 5c).
We next analyzed whether cytokine production could be
modulated by blocking TIGIT/ligand interactions using recom-
binant TIGIT-Fc molecules. As shown in Fig 6a, presence of
TIGIT-Fc resulted in impaired IFNg and IL-10 production in
T cells (Fig 6a). Notably, this effect was dependent on the pres-
ence of CLL cells, as in T cell solo cultures, cytokine production
was not significantly affected by addition of TIGIT-Fc (Fig 6b).
Finally, we tested whether the CLL-supportive function of
TIGITCT cells could also be recapitulated by blocking TIGIT/
ligand interactions using recombinant TIGIT-Fc molecules.
Therefore, we assessed CLL viability in co-culture assays in
Figure 4. CD4C TIGITC cells provide a supportive microenvironment for CLL cells. (a) Representative dot plots showing gating strategy for flow cytometric cell sorting.
(b) PBMCs have been depleted of TIGITC, PD-1C or TIGITCPD-1C CD4C or CD8C cells followed by incubation with CD3/CD28 activating beads. After 5 days in culture,
CLL viability was measured and corresponding T/ CLL ratios were analysed (nD 6) (c).
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response to 5 day anti-CD3/CD28 stimulation in presence or
absence of recombinant TIGIT-Fc. In experiments on 12 CLL
samples, we did not observe a significant impact on CLL sur-
vival, however, dividing samples in high and low expressing
TIGITCCD4CT cells based on ROC curve analysis using a cut-
off of 52.6% TIGITCcells within the CD4CT cell subset
(Fig 6c), we found a significant impact on CLL viability in the
TIGIThigh sample group (Fig 6c).
Discussion
In CLL, many alterations within the T cell compartment, such
as skewing towards effector and Treg subsets,31 abnormal CD4/
CD8 ratios,32 increased sensitivity of CD4C T cells towards
Fas-mediated apoptosis33 and the occurrence of expanded
monoclonal CD4C T cell populations have been observed.34,35
Also, an aberrant expression profile of inhibitory receptors
associated with T cell exhaustion has been noticed in CD4C
and CD8C T cells from CLL patients2 and within the CD8C T
cells, the expansion of PD-1 expressing cells featuring defects
in proliferation and cytotoxicity have been described.2,3 Fur-
thermore, in contrast to many aggressive tumors, CLL cells are
strongly depending on the microenvironment for proliferation
and survival1. In this regard, T cells were previously shown to
execute a substantial CLL-supportive function.29,36 Hence, a
more precise characterization of the CLL supportive T cell sub-
set would allow to specifically target this CLL/T cell interaction,
which would not only directly affect CLL viability but likely
also render CLL cells more vulnerable to conventional treat-
ment options. In this study, we found that particularly CD4C
T cells expressing the inhibitory receptor TIGIT were not only
increased in patients with an advanced disease stage but also
potent in increasing viability of autologous CLL cells in in vitro
co-culture assays. Moreover, we could show that this support-
ive impact on CLL viability of TIGIT expressing T cells is
dependent on TIGIT/ligand interactions, as this effect was tar-
getable by recombinant TIGIT-Fc molecules. In line with this,
we observed low but measurable levels of CD112 and CD155
on the surface of CLL cells, the ligands for TIGIT. Moreover,
we demonstrated that IFNg and IL-10 producing T cells were
enriched in the TIGITC compartment and blocking TIGIT/
ligand interactions suppressed the production of both IL-10
and IFNg. This effect was dependent on the presence of CLL
cells, further supporting a direct TIGIT mediated CLL/T cell
crosstalk, consistent with recent observations that expression of
these cytokines in T cells was increased upon TIGIT dependent
Figure 5. TIGITC cells display a distinct cytokine profile. (a) Representative dot plots showing intracellular cytokine production after cultivating CLL PBMCs for 24 h with
CD3/CD28 activating beads. (b) Cytokine production of TIGIT- or TIGITCCD4C T cells in 14 samples. (c) Mean fluorescence intensity ratio (MFIR) of CD155 and CD112 on
CD5CCD19C CLL (top) or CD5C T cells (bottom). The histograms show representative FACS plots of CLL cells (gated for CD5CCD19Ccells) and T cells (CD5C cells)
stained with isotype controls (in gray) and CD112/CD155 specific antibodies (in black). The dot plots show results from n D 14 samples.
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interaction with antigen-presenting cells.13,37 The prosurvival
effect of TIGITC T cells could well be based on secretion of
these cytokines. Alhough the proinflammatory cytokine IFNg
has been associated with cytotoxic and antitumor mecha-
nisms,38 IFNg can also exert protumorigenic effects. IFNg
attenuates programmed cell death in CLL cells in vitro,39 and
CLL T cells produce increased levels of IFNg, while CLL cells
show high expression of IFNg-receptors.40 These data support
an ambiguous role for IFNg, which depends on the cellular,
microenvironmental and molecular context.38
Recently, Joller et al. reported that TIGITC Tregs exhibit
superior immunosuppressive functions compared to the
TIGIT- counterpart.41 In this study, we observed a general
increase of Tregs and we found that more Tregs were express-
ing TIGIT in CLL patients compared to healthy controls. This
fits to the substantial IL-10 production in TIGITC CD4C T
cells from CLL patients as IL-10 not only dampens anti-tumor
responses in vivo, but also has a direct protective and prosur-
vival effect on CLL cells.42 In line with our data, it has been
recently reported that a subset of TIGITC circulating Tfh cells
have a strong B cell-supportive effect due to protective cytokine
secretion and high expression of costimulatory molecules.43
Additionally, the occurence of Tfh cells is significantly
increased in CLL, particularly in high risk patients.44
Our results are of particular interest in light of recent
approaches for anticancer immune therapies aiming at
blocking TIGIT to reinvigorate anticancer immune responses
(NCT02794571, NCT02913313; clinicaltrials.gov). Similar to
therapeutic antibodies for CTLA-4 (ipilimumab) and PD-1
(nivolumab and pembrolizumab) or its ligand PD-L1 (atezoli-
zumab, durvalumab), which have already been approved for
multiple hematological malignancies, antibodies blocking
TIGIT were developed to impede inhibitory signals on cyto-
toxic T cells in order to regain anti-tumor immunity.
In this regard, our own results suggest that anti-TIGIT
antibodies could specifically target the CLL-supportive
TIGITCCD4CT cell compartment, defining an alternative
rationale for using these antibodies especially in combination
with other treatment options.
Materials and methods
Patients
Peripheral blood samples were obtained from patients with
confirmed diagnosis of CLL (Department of Haematology and
Oncology, University Hospital Salzburg, Austria) on basis of
>5000 light chain restricted B cells and CD5, CD19, CD20low
and CD79blow co-expression per ml blood and twenty-nine
age-matched healthy control samples (Stroke Prevention
Center, Department of Neurology). Monoclonal antibodies for
flow cytometric analysis were provided by Beckman coulter:
Figure 6. TIGIT blockade decreases CLL viability and interferes with production of prosurvival cytokines. (a, b) Impact of TIGIT blockade on cytokine production by CD4C T
cells. PBMCs (upper panel; n D 12) or purified T cells (bottom panel; n D 10) were activated with CD3/CD28 beads for 24 h in the presence of recombinant TIGIT-Fc pro-
tein (rhTIGIT Fc) or corresponding isotype control and cytokines were quantifiued by intracellular FACS staining. (b) FACS analysis of surface expression of TIGIT was per-
formed on peripheral blood samples from CLL patients (n D 12). Plot of percentages of CD4CTIGITC T cells are shown, discriminating between TIGITlow (<52.6%
CD4CTIGITCcells) and TIGIThigh (>52.6% CD4CTIGITCcells). (c) Plot represents difference in CLL viability between TIGIT-Fc or isotype control treated samples. Viability
was determined by 7AAD/Annexin V staining after stimulating T/CLL co-cultures from TIGITlow (left) and TIGIThigh (right) patients shown in (b) using anti-CD3/CD28 beads
for 5 days in the presence of recombinant TIGIT-Fc or isotype control.
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CD5-PC7 (A21690), CD19-APC- Alexa Fluor 750 (A94681),
CD23-APC (A69964), CD20-Pacific Blue (B49208)and CD79b-
PE (IM1612). Of 114 measured patients, 36 received treatment
and 78 were chemona€ıve. Analysis of the mutational status of
immunoglobulin heavy chain variable region (IgVH), expres-
sion of CD38, ZAP70, CD49d and assessment of genomic aber-
rations (Tri12, delChr11q, delChr17p and delChr13q) was
performed as described previously(2). Overall 73.7% of patients
showed genomic aberrations. For detailed patient information
and treatment status see supplementary table 1 (samples used
for respective experiments are given on individual excel spread-
sheets within supplementary table 1). Full informed consent
was obtained from all CLL patients and healthy volunteers and
the study was conducted in accordance with institutional
Guidelines and the Declaration of Helsinki and under approval
of the Salzburg Ethics committee (no. 415-E/1287/4–2011 and
415-E/1287/13–2016). Peripheral blood mononuclear cells
(PBMCs) were collected in heparinized or EDTA-coated tubes
during routine examinations and separated by density centrifu-
gation using Biocoll (Biochrom AG).
Immunofluorescence staining and flow cytometric analysis
PBMCs were separated by density centrifugation of fresh CLL
blood samples. PBMCs were incubated with directly conjugated
mAbs for 20 minutes at room temperature. Flow cytometric
analysis was performed after erythrolysis with IOTest 3 Lys-
ing Solution (Beckman Coulter, IM3514) and washing steps.
Monoclonal antibodies for analysis were provided by Biole-
gend: anti-human PD-1-Brilliant Violet 421 (329920),CXCR3-
APC (353708), CXCR5-PerCP-Cy5.5 (356910), CCR4-PE-Cy7
(359410), CD62L-PerCP/Cy5.5 (304824) and CD226-PerCP/
Cy5.5 (338314). Monoclonal antibodies provided by Thermo-
Fisher included TIGIT-PE (12–9500-42), CD4-PE-Cyanine7
(25–0048-42), CD4-eFluor450 (48-0048-42), CD4-APC
(MHCD0405), 2B4-APC (17-5837-42), CD3-Alexa Fluor 700
(56-0032-82), CD3-FITC (11-0039-42), CD45RA-APC-
eFluor780 (47-0458-42), CD25-PE-Cyanine7 (25-0259-42),
CD127-APC-eFluor780 (47-1271-82), CD155-PE (12-1550-
41), CD112-APC (17-1128-42), CD19-FITC (11-0199-42),
rhAnnexin V-FITC (BMS147FI), 7-AAD Viability Staining
Solution (00-6993-50), TIM-3-PerCP-eFluor 710 (46-3109-42)
and CD8-Pacific Orange (MCD0830). For viability assays,
rhAnnexin V/FITC, 7-AAD Viability Staining Solution was
used. Data acquisition was performed on GalliosTM Flow
Cytometer research system (Beckman Coulter) and data analy-
sis was performed using Kaluza 1.2 Flow Cytometry Analysis
Software (Beckman Coulter).
Intracellular staining of cytokines
PBMCs were activated for 24 hours with CD3/CD28 coated
beads (ThermoFisher, 111.31D) with or without recombinant
human TIGIT Fc chimera protein, or the respective recombi-
nant human IgG1 Fc control (100 mg/mL, R&D Systems, 7898-
TG-050 and 110-HG). Monensin (ThermoFisher, 00-4505-51)
was added during the final four hours of culture. Intracellular
cytokines were stained with anti-human IFNg-FITC (Thermo-
Fisher,11-7319-82), IL-21-PE (ThermoFisher, 12-7219-42),
IL-10-PerCP-eFluor710 (ThermoFisher, 46-7108-42) and IL-4-
APC (ThermoFisher, 17-7049-42). For surface marker expres-
sion TIGIT-PE-Cyanine7 (ThermoFisher, 25-9500-42), CD3-
AF700 (ThermoFisher, 56-0038-42) and CD4-Brilliant Violet
650 (Biolegend, 300536) were used.
Depletion of T cells for in vitro co-culture experiments
The impact of specific T cells on the viability of autologous CLL
cells was assessed in in vitro experiments. To deplete PBMCs
from TIGITC and/or PD1C cells, we stained PBMCs using
TIGIT or PD1 antibodies and depleted positive cells by flow
cytometric cell sorting (FACS Aria III, Becton Dickinson). To
deplete PBMCs from all CD8C T cells together with TIGITC
or PD-1C cells (to keep CD4CTIGIT- or PD-1- T cells in co-
culture with CLL cells) we stained PBMCs using TIGIT or PD-
1 and CD8 antibodies and depleted positive cells by flow cyto-
metric cell sorting. To deplete PBMCs from all CD4C T cells
together with TIGITC or PD-1C cells (to keep CD8CTIGIT-
or PD-1- T cells in co-culture with CLL cells) we stained
PBMCs using TIGIT and CD4 antibodies and depleted positive
cells by flow cytometric cell sorting Purity of sorted cells was
>92% for all experiments. Similar to Chauvin et al.,24 sorted
PBMCs were stimulated in vitro with anti-CD3/CD28 coated
beads (ThermoFisher). After five days CLL and T cells were
stained with rhAnnexin V-FITC and 7-AAD Viability Staining
Solution (ThermoFisher) and analyzed on a GalliosTM Flow
Cytometer research system.
Blockade of TIGIT/PVRp
PBMCs were activated for five days with CD3/CD28 coated
beads (ThermoFisher) in presence of recombinant human
TIGIT Fc chimera protein or recombinant human IgG1 Fc con-
trol (100 mg/mL, R&D System). Antibodies used for viability
stain were anti-CD5-AF700 (Beckman Coulter, A78835),
CD19-PE, rhAnnexin V-FITC and 7-AAD Viability Staining
Solution (ThermoFisher).
Statistical analysis
Statistical analyses were performed using Graph Pad Prism
Version 5.02 (GraphPad Software, Inc.). Data are presented
either as dot plots or as box plots showing 25th and 75th percen-
tile and median inside the box. Whiskers represent minimum
to maximum of all data.
Correlations were performed using the parametric
pearson or nonparameric spearman test
Data was compared depending on Gaussian distribution
(unpaired t test/ paired t test or Mann-Whitney test/ Wilcoxon
matched pairs test). P values of less than 0.05 were considered
statistically significant (p < 0.05, p < 0.01, p < 0.001).
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